IL131016A - Selection of proteins using RNA-protein blends - Google Patents

Selection of proteins using RNA-protein blends

Info

Publication number: IL131016A
Authority: IL; Israel
Prior art keywords: protein; rna; candidate; fusion; sequence
Prior art date: 1997-01-21

Application number

IL13101698A

Other languages

English (en)

Hebrew (he)

Other versions

IL131016A0 (en

Original Assignee

Gen Hospital Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-01-21

Filing date

1998-01-14

Publication date

2004-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL131016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-01-14 Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp

2001-01-28 Publication of IL131016A0 publication Critical patent/IL131016A0/xx

2004-12-15 Publication of IL131016A publication Critical patent/IL131016A/en

Links

230000004927 fusion Effects 0.000 title claims abstract description 257
108090000623 proteins and genes Proteins 0.000 title claims abstract description 186
102000004169 proteins and genes Human genes 0.000 title claims abstract description 181
238000000034 method Methods 0.000 claims abstract description 126
RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical group C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 claims description 169
238000006243 chemical reaction Methods 0.000 claims description 153
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 143
238000013519 translation Methods 0.000 claims description 123
108090000765 processed proteins & peptides Proteins 0.000 claims description 102
108020004414 DNA Proteins 0.000 claims description 95
229950010131 puromycin Drugs 0.000 claims description 95
238000000338 in vitro Methods 0.000 claims description 64
108020004999 messenger RNA Proteins 0.000 claims description 53
108091026890 Coding region Proteins 0.000 claims description 50
238000009739 binding Methods 0.000 claims description 48
230000027455 binding Effects 0.000 claims description 47
238000011534 incubation Methods 0.000 claims description 45
239000006166 lysate Substances 0.000 claims description 32
150000007523 nucleic acids Chemical class 0.000 claims description 30
102000039446 nucleic acids Human genes 0.000 claims description 28
108020004707 nucleic acids Proteins 0.000 claims description 28
210000001995 reticulocyte Anatomy 0.000 claims description 24
239000007787 solid Substances 0.000 claims description 23
108091081024 Start codon Proteins 0.000 claims description 18
102000053602 DNA Human genes 0.000 claims description 17
239000000284 extract Substances 0.000 claims description 16
230000014621 translational initiation Effects 0.000 claims description 16
238000011065 in-situ storage Methods 0.000 claims description 14
229920002477 rna polymer Polymers 0.000 claims description 14
241000209140 Triticum Species 0.000 claims description 12
235000021307 Triticum Nutrition 0.000 claims description 12
230000001580 bacterial effect Effects 0.000 claims description 9
210000004027 cell Anatomy 0.000 claims description 7
210000003527 eukaryotic cell Anatomy 0.000 claims description 5
238000003776 cleavage reaction Methods 0.000 claims description 3
210000001236 prokaryotic cell Anatomy 0.000 claims description 3
230000007017 scission Effects 0.000 claims description 3
230000005714 functional activity Effects 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 1
239000003153 chemical reaction reagent Substances 0.000 abstract description 9
235000018102 proteins Nutrition 0.000 description 130
230000014616 translation Effects 0.000 description 116
239000000047 product Substances 0.000 description 80
230000015572 biosynthetic process Effects 0.000 description 57
238000002955 isolation Methods 0.000 description 45
108091034117 Oligonucleotide Proteins 0.000 description 42
239000000370 acceptor Substances 0.000 description 38
238000013459 approach Methods 0.000 description 37
238000003786 synthesis reaction Methods 0.000 description 36
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
239000002585 base Substances 0.000 description 29
239000000523 sample Substances 0.000 description 27
229920002684 Sepharose Polymers 0.000 description 24
239000000203 mixture Substances 0.000 description 24
239000002773 nucleotide Substances 0.000 description 24
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 23
238000002474 experimental method Methods 0.000 description 23
238000001114 immunoprecipitation Methods 0.000 description 23
229930182817 methionine Natural products 0.000 description 23
125000003729 nucleotide group Chemical group 0.000 description 23
150000001413 amino acids Chemical group 0.000 description 22
239000000463 material Substances 0.000 description 22
239000000499 gel Substances 0.000 description 21
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 20
239000005289 controlled pore glass Substances 0.000 description 20
230000006870 function Effects 0.000 description 20
229920000936 Agarose Polymers 0.000 description 19
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
108091028043 Nucleic acid sequence Proteins 0.000 description 18
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
235000001014 amino acid Nutrition 0.000 description 18
238000007792 addition Methods 0.000 description 17
239000000872 buffer Substances 0.000 description 17
239000000562 conjugate Substances 0.000 description 17
238000013518 transcription Methods 0.000 description 17
230000035897 transcription Effects 0.000 description 17
101710135898 Myc proto-oncogene protein Proteins 0.000 description 16
102100038895 Myc proto-oncogene protein Human genes 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
101710150448 Transcriptional regulator Myc Proteins 0.000 description 16
230000037230 mobility Effects 0.000 description 16
230000001323 posttranslational effect Effects 0.000 description 16
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 15
102000004190 Enzymes Human genes 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 15
102100021519 Hemoglobin subunit beta Human genes 0.000 description 15
108091005904 Hemoglobin subunit beta Proteins 0.000 description 15
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
-1 aminohexyl Chemical group 0.000 description 15
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 13
102000005891 Pancreatic ribonuclease Human genes 0.000 description 13
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 13
239000011541 reaction mixture Substances 0.000 description 13
238000010839 reverse transcription Methods 0.000 description 13
125000004035 thiopropyl group Chemical group [H]SC([H])([H])C([H])([H])C([H])([H])* 0.000 description 13
108020004705 Codon Proteins 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
230000008901 benefit Effects 0.000 description 12
238000011160 research Methods 0.000 description 12
241000588724 Escherichia coli Species 0.000 description 11
230000003197 catalytic effect Effects 0.000 description 11
239000003480 eluent Substances 0.000 description 11
238000005516 engineering process Methods 0.000 description 11
238000010348 incorporation Methods 0.000 description 11
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 11
238000000746 purification Methods 0.000 description 11
239000000243 solution Substances 0.000 description 11
108010051423 streptavidin-agarose Proteins 0.000 description 11
239000000126 substance Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
102100034343 Integrase Human genes 0.000 description 10
108700026244 Open Reading Frames Proteins 0.000 description 10
108020004566 Transfer RNA Proteins 0.000 description 10
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
101710120037 Toxin CcdB Proteins 0.000 description 9
230000003321 amplification Effects 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
238000010828 elution Methods 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
238000003199 nucleic acid amplification method Methods 0.000 description 9
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
238000005119 centrifugation Methods 0.000 description 8
230000000295 complement effect Effects 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
239000013024 dilution buffer Substances 0.000 description 8
239000002002 slurry Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000000758 substrate Substances 0.000 description 8
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
229960000549 4-dimethylaminophenol Drugs 0.000 description 7
102000012410 DNA Ligases Human genes 0.000 description 7
108010061982 DNA Ligases Proteins 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
238000006731 degradation reaction Methods 0.000 description 7
238000002515 oligonucleotide synthesis Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
108020003589 5' Untranslated Regions Proteins 0.000 description 6
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 6
108090000279 Peptidyltransferases Proteins 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
150000001408 amides Chemical class 0.000 description 6
235000011114 ammonium hydroxide Nutrition 0.000 description 6
230000008859 change Effects 0.000 description 6
238000013461 design Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
239000010931 gold Substances 0.000 description 6
229910052737 gold Inorganic materials 0.000 description 6
238000002372 labelling Methods 0.000 description 6
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000010187 selection method Methods 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
238000005406 washing Methods 0.000 description 6
108020004635 Complementary DNA Proteins 0.000 description 5
108010067770 Endopeptidase K Proteins 0.000 description 5
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 5
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 5
241000723873 Tobacco mosaic virus Species 0.000 description 5
229920004890 Triton X-100 Polymers 0.000 description 5
239000013504 Triton X-100 Substances 0.000 description 5
239000002253 acid Substances 0.000 description 5
150000007513 acids Chemical class 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000004202 carbamide Substances 0.000 description 5
239000003054 catalyst Substances 0.000 description 5
239000012634 fragment Substances 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
150000008300 phosphoramidites Chemical class 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
125000002652 ribonucleotide group Chemical group 0.000 description 5
210000003705 ribosome Anatomy 0.000 description 5
238000003756 stirring Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
239000002126 C01EB10 - Adenosine Substances 0.000 description 4
102000016911 Deoxyribonucleases Human genes 0.000 description 4
108010053770 Deoxyribonucleases Proteins 0.000 description 4
229910004373 HOAc Inorganic materials 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
239000004365 Protease Substances 0.000 description 4
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
102000006382 Ribonucleases Human genes 0.000 description 4
108010083644 Ribonucleases Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
229960005305 adenosine Drugs 0.000 description 4
238000001042 affinity chromatography Methods 0.000 description 4
125000003277 amino group Chemical group 0.000 description 4
238000000137 annealing Methods 0.000 description 4
238000010276 construction Methods 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
230000005021 gait Effects 0.000 description 4
230000002068 genetic effect Effects 0.000 description 4
239000011521 glass Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000012160 loading buffer Substances 0.000 description 4
229910001629 magnesium chloride Inorganic materials 0.000 description 4
238000005457 optimization Methods 0.000 description 4
238000002823 phage display Methods 0.000 description 4
229920002401 polyacrylamide Polymers 0.000 description 4
230000008569 process Effects 0.000 description 4
235000019419 proteases Nutrition 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
AMNAZJFEONUVTD-QJHHURCWSA-N (2s,3s,4s,5r,6r)-6-(4-amino-2-oxopyrimidin-1-yl)-4,5-dihydroxy-3-[[(2r)-3-hydroxy-2-[[2-(methylamino)acetyl]amino]propanoyl]amino]oxane-2-carboxamide Chemical compound O1[C@H](C(N)=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC)[C@H](O)[C@@H](O)[C@@H]1N1C(=O)N=C(N)C=C1 AMNAZJFEONUVTD-QJHHURCWSA-N 0.000 description 3
108020004465 16S ribosomal RNA Proteins 0.000 description 3
FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZXFLCMHBSA-N 5-[(3ar,4r,6as)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoic acid Chemical compound N1C(=O)N[C@H]2[C@@H](CCCCC(=O)O)SC[C@H]21 YBJHBAHKTGYVGT-ZXFLCMHBSA-N 0.000 description 3
238000000018 DNA microarray Methods 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
FEACDOXQOYCHKU-UHFFFAOYSA-N Gougerotin Natural products CNCC(=O)NC1=NC(=O)N(C=C1)C2OC(C(O)C(NC(=O)C(N)CO)C2O)C(=O)N FEACDOXQOYCHKU-UHFFFAOYSA-N 0.000 description 3
101710203526 Integrase Proteins 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
150000008575 L-amino acids Chemical class 0.000 description 3
PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 description 3
GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
229920002352 Peptidyl-tRNA Polymers 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
238000000376 autoradiography Methods 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000029087 digestion Effects 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
230000000670 limiting effect Effects 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
238000000329 molecular dynamics simulation Methods 0.000 description 3
239000000178 monomer Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
229940014800 succinic anhydride Drugs 0.000 description 3
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
CTFJATOFOZBFPT-UCTKEYDRSA-N (2s)-2-amino-1-[(2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3-phenylpropan-1-one Chemical compound C([C@H](N)C(=O)[C@@]1([C@@H]([C@H](O)[C@@H](CO)O1)O)N1C2=NC=NC(N)=C2N=C1)C1=CC=CC=C1 CTFJATOFOZBFPT-UCTKEYDRSA-N 0.000 description 2
BLOMDWFVDQMXKC-GFYCOGQESA-N (2s)-2-amino-1-[(2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]propan-1-one Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(C(=O)[C@@H](N)C)O[C@H](CO)[C@@H](O)[C@H]1O BLOMDWFVDQMXKC-GFYCOGQESA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
MISJXUDJCSZFAH-UHFFFAOYSA-N 1-sulfanylpyridin-2-one Chemical compound SN1C=CC=CC1=O MISJXUDJCSZFAH-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
108020005345 3' Untranslated Regions Proteins 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
229930024421 Adenine Natural products 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
108010054278 Lac Repressors Proteins 0.000 description 2
108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
MVTQIFVKRXBCHS-SMMNFGSLSA-N N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide (10R,11R,12E,17E,19E,21S)-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),6,12,17,19,25(28)-hexaene-2,8,14,23-tetrone Chemical compound CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c2coc(CC(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@H]1C)n2.CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccccc2)N(C)C(=O)[C@@H]2CCCN2C1=O)c1ccccc1 MVTQIFVKRXBCHS-SMMNFGSLSA-N 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108700020796 Oncogene Proteins 0.000 description 2
102000001253 Protein Kinase Human genes 0.000 description 2
108091028664 Ribonucleotide Proteins 0.000 description 2
102000002278 Ribosomal Proteins Human genes 0.000 description 2
108010000605 Ribosomal Proteins Proteins 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
108010006785 Taq Polymerase Proteins 0.000 description 2
108010080702 Virginiamycin Proteins 0.000 description 2
239000004188 Virginiamycin Substances 0.000 description 2
241000269370 Xenopus <genus> Species 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
150000003838 adenosines Chemical class 0.000 description 2
238000013019 agitation Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
238000003491 array Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
230000008033 biological extinction Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
238000011033 desalting Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000012869 ethanol precipitation Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
238000012248 genetic selection Methods 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000012133 immunoprecipitate Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000005192 partition Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
108060006633 protein kinase Proteins 0.000 description 2
230000004850 protein–protein interaction Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000002336 ribonucleotide Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000003345 scintillation counting Methods 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
238000010512 small scale reaction Methods 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
229940063673 spermidine Drugs 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
150000003573 thiols Chemical class 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
238000006276 transfer reaction Methods 0.000 description 2
239000003558 transferase inhibitor Substances 0.000 description 2
230000007704 transition Effects 0.000 description 2
230000005945 translocation Effects 0.000 description 2
JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
230000035899 viability Effects 0.000 description 2
229960003842 virginiamycin Drugs 0.000 description 2
235000019373 virginiamycin Nutrition 0.000 description 2
YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
JNJRULCXXGGTRN-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2,3-dimethylbenzene Chemical compound CC1=CC=CC(C(Cl)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1C JNJRULCXXGGTRN-UHFFFAOYSA-N 0.000 description 1
125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
102000057234 Acyl transferases Human genes 0.000 description 1
101000689231 Aeromonas salmonicida S-layer protein Proteins 0.000 description 1
102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 1
241001156002 Anthonomus pomorum Species 0.000 description 1
108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
108091023037 Aptamer Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102100021391 Cationic amino acid transporter 3 Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
101710096438 DNA-binding protein Proteins 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
241000701533 Escherichia virus T4 Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000016397 Methyltransferase Human genes 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000002798 Phenylalanine-tRNA Ligase Human genes 0.000 description 1
108010004478 Phenylalanine-tRNA Ligase Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
108700040121 Protein Methyltransferases Proteins 0.000 description 1
101710086015 RNA ligase Proteins 0.000 description 1
108010065868 RNA polymerase SP6 Proteins 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
108091006230 SLC7A3 Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
101000748795 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) Cytochrome c oxidase polypeptide I+III Proteins 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
238000007259 addition reaction Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000007801 affinity label Substances 0.000 description 1
238000003314 affinity selection Methods 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000012501 chromatography medium Substances 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
WUESWDIHTKHGQA-UHFFFAOYSA-N cyclohexylurea Chemical compound NC(=O)NC1CCCCC1 WUESWDIHTKHGQA-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
125000002637 deoxyribonucleotide group Chemical class 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
229960002694 emetine Drugs 0.000 description 1
AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000007429 general method Methods 0.000 description 1
102000018146 globin Human genes 0.000 description 1
108060003196 globin Proteins 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
229940025294 hemin Drugs 0.000 description 1
BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
108091008039 hormone receptors Proteins 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000008629 immune suppression Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000002621 immunoprecipitating effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000005304 joining Methods 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000010667 large scale reaction Methods 0.000 description 1
239000002523 lectin Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000009149 molecular binding Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000036438 mutation frequency Effects 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
238000012803 optimization experiment Methods 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
235000011056 potassium acetate Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108010057123 protein acyltransferase Proteins 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
XKLZIVIOZDNKEQ-CLQLPEFOSA-N sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
229950009641 sparsomycin Drugs 0.000 description 1
XKLZIVIOZDNKEQ-UHFFFAOYSA-N sparsomycin Natural products CSCS(=O)CC(CO)NC(=O)C=CC1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1062—Isolating an individual clone by screening libraries mRNA-Display, e.g. polypeptide and encoding template are connected covalently
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B30/00—Methods of screening libraries
- C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Bioinformatics & Computational Biology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Crystallography & Structural Chemistry (AREA)
Plant Pathology (AREA)
Cell Biology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

IL13101698A 1997-01-21 1998-01-14 Selection of proteins using RNA-protein blends IL131016A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3596397P	1997-01-21	1997-01-21
US6449197P	1997-11-06	1997-11-06
PCT/US1998/000807 WO1998031700A1 (en)	1997-01-21	1998-01-14	Selection of proteins using rna-protein fusions

Publications (2)

Publication Number	Publication Date
IL131016A0 IL131016A0 (en)	2001-01-28
IL131016A true IL131016A (en)	2004-12-15

Family

ID=26712662

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL13101698A IL131016A (en)	1997-01-21	1998-01-14	Selection of proteins using RNA-protein blends

Country Status (16)

Country	Link
US (5)	US6258558B1 (de)
EP (2)	EP1712623B1 (de)
JP (1)	JP3692542B2 (de)
KR (1)	KR100566859B1 (de)
CN (1)	CN1238366C (de)
AT (2)	ATE332368T1 (de)
AU (1)	AU738328B2 (de)
CA (1)	CA2278786C (de)
DE (1)	DE69835143T2 (de)
DK (2)	DK1712623T3 (de)
ES (2)	ES2268763T3 (de)
IL (1)	IL131016A (de)
PT (2)	PT1712623E (de)
RU (1)	RU2233878C2 (de)
TW (1)	TW589323B (de)
WO (1)	WO1998031700A1 (de)

Families Citing this family (452)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0368684B2 (de) *	1988-11-11	2004-09-29	Medical Research Council	Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
DE69730157T2 (de) *	1996-10-17	2005-07-28	Mitsubishi Chemical Corp.	Molekül, welches genotyp und phänotyp zusammenführt und dessen anwendungen
US6261804B1 (en) *	1997-01-21	2001-07-17	The General Hospital Corporation	Selection of proteins using RNA-protein fusions
US8207093B2 (en)	1997-01-21	2012-06-26	The General Hospital Corporation	Selection of proteins using RNA-protein fusions
ES2230701T3 (es)	1997-07-07	2005-05-01	Medical Research Council	Procedimiento de seleccion in vitro.
US6242246B1 (en)	1997-12-15	2001-06-05	Somalogic, Inc.	Nucleic acid ligand diagnostic Biochip
US20070166741A1 (en)	1998-12-14	2007-07-19	Somalogic, Incorporated	Multiplexed analyses of test samples
US20060057573A1 (en) *	2002-02-15	2006-03-16	Somalogic, Inc	Methods and reagents for detecting target binding by nucleic acid ligands
CA2323638A1 (en)	1998-04-03	1999-10-14	Phylos, Inc.	Addressable protein arrays
US6440695B1 (en)	1998-04-17	2002-08-27	Whitehead Institute For Biomedical Research	Method for producing diverse libraries of encoded polypeptides
US20030170820A1 (en) *	1998-05-08	2003-09-11	Gregory Coia	Continuous in- vitro evolution
JP4240574B2 (ja) *	1998-05-15	2009-03-18	三菱化学株式会社	タンパク質のラベル化組成物およびタンパク質のラベル化方法
US6287765B1 (en) *	1998-05-20	2001-09-11	Molecular Machines, Inc.	Methods for detecting and identifying single molecules
JP2002522091A (ja) *	1998-08-17	2002-07-23	フィロスインク．	３’非翻訳領域を欠損する核酸を生成して細胞ｒｎａ蛋白質融合体形成を最適化する方法
JP4278872B2 (ja) *	1998-08-17	2009-06-17	フィロスインク．	蛋白質・核酸融合分子ライブラリーを用いた化合物・蛋白質相互作用の同定
AU2004200998B2 (en) *	1998-08-17	2007-01-11	Compound Therapeutics, Inc.	Methods for producing nucleic acids lacking 3'-untranslated regions and optimizing cellular RNA-protein fusion formation
NZ511699A (en) *	1998-12-02	2003-02-28	Phylos Inc	DNA-protein fusions and uses thereof
DK1137941T4 (da) *	1998-12-10	2014-01-06	Brystol Myers Squibb Company	Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US7115396B2 (en) *	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
AU2004242526B2 (en) *	1999-01-07	2007-08-30	United Kingdom Research And Innovation	Optical Sorting Method
GB9900298D0 (en) *	1999-01-07	1999-02-24	Medical Res Council	Optical sorting method
AU4231000A (en)	1999-04-12	2000-11-14	Johns Hopkins University School Of Medicine, The	In vitro ribosome evolution
DE19923966C2 (de) *	1999-05-25	2003-04-24	Phylos Inc	Erkennungssystem zur Auftrennung von Probenbestandteilen, seine Herstellung und Verwendung
US6623926B1 (en)	1999-06-01	2003-09-23	Phylos, Inc.	Methods for producing 5′-nucleic acid-protein conjugates
AU778194B2 (en) *	1999-07-12	2004-11-18	Bristol-Myers Squibb Company	C-terminal protein tagging
AU2008200974B2 (en) *	1999-07-27	2012-05-03	Bristol-Myers Squibb Company	Peptide acceptor ligation methods
DK1196637T3 (da) *	1999-07-27	2007-07-30	Adnexus Therapeutics Inc	Peptidacceptor-ligeringsmetoder
US6436665B1 (en)	1999-08-27	2002-08-20	Phylos, Inc	Methods for encoding and sorting in vitro translated proteins
WO2001025249A1 (en) *	1999-10-01	2001-04-12	Zhongping Yu	Compositions and methods for identifying polypeptides and nucleic acid molecules
DE19959857C1 (de) *	1999-12-10	2001-06-28	Aventis Res & Tech Gmbh & Co	Testsystem zum Nachweis von Analyten sowie ein Verfahren zur Herstellung und Verwendung
IL150291A0 (en) *	2000-01-11	2002-12-01	Maxygen Inc	Integrated systems and methods for diversity generation and screening
DE60118527D1 (de) *	2000-01-24	2006-05-18	Compound Therapeutics Inc	Sensible und multiplexe diagnostische tests zur proteinanalyse
US7022479B2 (en) *	2000-01-24	2006-04-04	Compound Therapeutics, Inc.	Sensitive, multiplexed diagnostic assays for protein analysis
AU4329001A (en) *	2000-02-24	2001-09-03	Compound Therapeutics, Inc.	Improved methods for generating catalytic proteins
US6489106B1 (en) *	2000-03-10	2002-12-03	Nec Research Institute, Inc.	Control of the expression of anchored genes using micron scale heaters
US8288322B2 (en)	2000-04-17	2012-10-16	Dyax Corp.	Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
WO2001083507A1 (en) *	2000-05-05	2001-11-08	Selegen	Identification of polypeptides and nucleic acid molecules using linkage between dna and polypeptide
US6962781B1 (en)	2000-05-19	2005-11-08	Proteonova, Inc.	In vitro evolution of nucleic acids and encoded polypeptide
ATE369442T1 (de) *	2000-05-19	2007-08-15	Richard B Williams	In vitro evolution von nukleinsäuren und kodierten polypeptiden
US7410761B2 (en)	2000-05-19	2008-08-12	Proteonova, Inc.	System for rapid identification and selection of nucleic acids and polypeptides, and method thereof
US20040229271A1 (en) *	2000-05-19	2004-11-18	Williams Richard B.	Compositions and methods for the identification and selection of nucleic acids and polypeptides
KR100919593B1 (ko)	2000-06-29	2009-09-29	아보트 러보러터리즈	이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
DE10033194C2 (de) *	2000-07-07	2002-07-18	Aventis Res & Tech Gmbh & Co	Biosonden und deren Verwendung
CA2419490C (en)	2000-08-15	2010-01-26	Discerna Limited	Functional protein arrays
DE10041238A1 (de) *	2000-08-22	2002-03-07	Aventis Res & Tech Gmbh & Co	Verfahren zur Identifizierung spezifisch spaltbarer peptide und Verwendung solcher Peptidsequenzen
DE60143959D1 (de)	2000-08-25	2011-03-10	Basf Plant Science Gmbh	En kodieren
EP2141243A3 (de)	2000-10-16	2010-01-27	Brystol-Myers Squibb Company	Proteingerüste für Antikörpermimetika und andere Bindungsproteine
US6841359B2 (en)	2000-10-31	2005-01-11	The General Hospital Corporation	Streptavidin-binding peptides and uses thereof
JP4516273B2 (ja) *	2000-11-15	2010-08-04	ミナーヴァ・バイオテクノロジーズ・コーポレーション	オリゴヌクレオチド識別子
EP1350846A4 (de) *	2000-12-07	2005-01-26	Univ Keio	C-terminales modifiziertes protein und verfahren zu seiner herstellung, bei der herstellung von c-terminalem modifiziertem protein zu verwendendes modifikationsmittel und translationsvorlage und verfahren zum nachweis von proteinwechselwirkung unter verwendung des c-terminalen modifizierten proteins
JP4963142B2 (ja) *	2000-12-14	2012-06-27	学校法人慶應義塾	遺伝子型と表現型の対応付け分子とその構成要素、および対応付け分子の製造方法と利用方法
WO2002057293A2 (en) *	2001-01-22	2002-07-25	Sangamo Biosciences, Inc.	Modified zinc finger binding proteins
US6800453B2 (en)	2001-01-23	2004-10-05	President And Fellows Of Harvard College	Nucleic-acid programmable protein arrays
EP1423400B2 (de) *	2001-03-19	2013-05-22	President and Fellows of Harvard College	Entwicklung neuer molekularer funktionen
EP1507860A4 (de) *	2001-04-02	2005-08-03	Univ Washington	Referenzwerkzeuge für dynamische aktionen
AU2002256076A1 (en) *	2001-04-10	2002-10-28	Interlock Industries, Inc.	Water based adhesive
JP2008099700A (ja) *	2001-05-11	2008-05-01	National Institute Of Advanced Industrial & Technology	任意のポリペプチドをコードするＤＮＡの転写産物と翻訳産物との安定的な複合体を形成させる方法、該方法に用いる核酸構築物、該方法により形成される複合体、並びに該方法を利用した機能性タンパク質および該タンパク質をコードするｍＲＮＡまたはＤＮＡのスクリーニング
EP1401850A1 (de)	2001-06-20	2004-03-31	Nuevolution A/S	Nukleosidderivate zur herstellung einer verbindungsbibliothek
US20060234231A1 (en) *	2001-06-20	2006-10-19	Nuevolution A/S	Microarrays displaying encoded molecules
IL159268A0 (en) *	2001-06-20	2004-06-01	Nuevolution As	Templated molecules and methods for using such molecules
US20040161741A1 (en)	2001-06-30	2004-08-19	Elazar Rabani	Novel compositions and processes for analyte detection, quantification and amplification
US9777312B2 (en)	2001-06-30	2017-10-03	Enzo Life Sciences, Inc.	Dual polarity analysis of nucleic acids
US20030143612A1 (en) *	2001-07-18	2003-07-31	Pointilliste, Inc.	Collections of binding proteins and tags and uses thereof for nested sorting and high throughput screening
US20030027194A1 (en) *	2001-07-31	2003-02-06	Markus Kurz	Modular assembly of nucleic acid-protein fusion multimers
US7172905B2 (en)	2001-08-07	2007-02-06	The University Of Chicago	Polypeptide immobilization
DE10147074A1 (de) *	2001-09-25	2003-05-08	Beru Ag	Verfahren zum Betreiben einer aus mehreren Heizelementen bestehenden mehrstufigen elektrischen Heizung
GB0127564D0 (en)	2001-11-16	2002-01-09	Medical Res Council	Emulsion compositions
AU2002367566B2 (en)	2001-11-20	2008-10-16	Duke University	Interfacial biomaterials
AU2002365404A1 (en) *	2001-11-27	2003-06-10	Compound Therapeutics, Inc.	Solid-phase immobilization of proteins and peptides
US7262054B2 (en) *	2002-01-22	2007-08-28	Sangamo Biosciences, Inc.	Zinc finger proteins for DNA binding and gene regulation in plants
DE20200926U1 (de) *	2002-01-23	2002-04-18	Hegenscheidt-MFD GmbH & Co. KG, 41812 Erkelenz	Festwalzgerät einer Festwalzmaschine für Kurbelwellen
JP2003299489A (ja) *	2002-02-08	2003-10-21	Mitsubishi Chemicals Corp	核酸構築物
US10731151B2 (en)	2002-03-15	2020-08-04	Nuevolution A/S	Method for synthesising templated molecules
WO2003078627A2 (en) *	2002-03-15	2003-09-25	Nuevolution A/S	A building block capable of functional entity transfer to nucleophil
AU2003214031A1 (en) *	2002-03-15	2003-09-29	Nuevolution A/S	An improved method for synthesising templated molecules
WO2003078050A2 (en) *	2002-03-15	2003-09-25	Nuevolution A/S	A building block forming a c-c bond upon reaction
US20050247001A1 (en) *	2002-03-15	2005-11-10	Nuevolution A/S	Building block forming a c-c or a c-hetero atom bond uponreaction
NO20021298L (no) *	2002-03-15	2003-09-16	Bjoern H Lindqvist	Metoder for peptid og protein påvisning i nukleinsyre chip- arrays
WO2003089454A2 (en) *	2002-04-19	2003-10-30	California Institute Of Technology	Unnatural amino acid containing display libraries
US20030198973A1 (en) *	2002-04-23	2003-10-23	The Molecular Sciences Institute, Inc.	Chimeric fusion molecule for analyte detection and quantitation
US20060073481A1 (en) *	2002-04-23	2006-04-06	The Molecular Sciences Institute	Formation and use of site specific nucleic acid coupled binding polypeptides
US20030198967A1 (en) *	2002-04-23	2003-10-23	Matson Robert S.	Multi-functional microarrays and methods
EP1520040A2 (de) *	2002-06-20	2005-04-06	Nuevolution A/S	Mikroarrays zur darstellung von kodierten molekülen
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
EP1521961A2 (de) *	2002-07-05	2005-04-13	The University of Chicago	Charakterisierung von biochips mit selbstausgerichteten monoschichten mittels maldi-tof-ms
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
DK2314629T4 (da)	2002-07-18	2023-02-06	Merus Nv	Rekombinant produktion af blandinger af antistoffer
EP1539980B1 (de) *	2002-08-01	2016-02-17	Nuevolution A/S	MEHRSTUFENSYNTHESE VON MIT MATRIZEN ASSOZIIERTE MOLEKüLEN
WO2004016767A2 (en) *	2002-08-19	2004-02-26	The President And Fellows Of Harvard College	Evolving new molecular function
US20040043384A1 (en) *	2002-08-28	2004-03-04	Oleinikov Andrew V.	In vitro protein translation microarray device
US7361635B2 (en) *	2002-08-29	2008-04-22	Sangamo Biosciences, Inc.	Simultaneous modulation of multiple genes
US7354750B2 (en) *	2002-10-18	2008-04-08	Promega Corporation	Methods for separating molecules
AU2011226815B2 (en) *	2002-10-30	2014-09-25	Nuevolution A/S	Enzymatic encoding
EP2348124B1 (de) *	2002-10-30	2013-12-11	Nuevolution A/S	Synthese bifunktioneller Komplexe
WO2004056994A2 (en)	2002-12-19	2004-07-08	Nuevolution A/S	Quasirandom structure and function guided synthesis methods
US7083948B1 (en) *	2002-12-24	2006-08-01	Immunex Corporation	Polypeptide purification reagents and methods for their use
CA2513899C (en)	2003-01-29	2013-03-26	454 Corporation	Methods of amplifying and sequencing nucleic acids
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR100858081B1 (ko) *	2003-02-14	2008-09-10	삼성전자주식회사	유전정보 코딩장치 및 방법
WO2004074501A2 (en) *	2003-02-21	2004-09-02	Nuevolution A/S	A method for obtaining structural information about an encoded molecule
US20070026397A1 (en)	2003-02-21	2007-02-01	Nuevolution A/S	Method for producing second-generation library
US7915201B2 (en)	2003-03-20	2011-03-29	Nuevolution A/S	Ligational encoding of small molecules
US8017323B2 (en) *	2003-03-26	2011-09-13	President And Fellows Of Harvard College	Free reactant use in nucleic acid-templated synthesis
WO2004087730A2 (en) *	2003-03-27	2004-10-14	The Johns Hopkins University	Method for producing diverse libraries of encoded polymers
US20060078893A1 (en)	2004-10-12	2006-04-13	Medical Research Council	Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en)	2003-03-31	2003-05-07	Medical Res Council	Selection by compartmentalised screening
GB0307428D0 (en)	2003-03-31	2003-05-07	Medical Res Council	Compartmentalised combinatorial chemistry
US20050079546A1 (en) *	2003-05-01	2005-04-14	Dasa Lipovsek	Serum albumin scaffold-based proteins and uses thereof
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
WO2004106375A1 (en)	2003-05-30	2004-12-09	Merus Biopharmaceuticals B.V. I.O.	Fab library for the preparation of anti vegf and anti rabies virus fabs
WO2004110964A2 (en) *	2003-06-16	2004-12-23	Nuevolution A/S	Encoded molecules by translation (emt)
US8048627B2 (en)	2003-07-05	2011-11-01	The Johns Hopkins University	Method and compositions for detection and enumeration of genetic variations
EP2272566A3 (de)	2003-08-18	2013-01-02	MedImmune, LLC	Humanisierung von antikörpern
US11118215B2 (en)	2003-09-18	2021-09-14	Nuevolution A/S	Method for obtaining structural information concerning an encoded molecule and method for selecting compounds
US20080220049A1 (en) *	2003-12-05	2008-09-11	Adnexus, A Bristol-Myers Squibb R&D Company	Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
EP1711196A4 (de)	2003-12-05	2011-09-14	Bristol Myers Squibb Co	Inhibitoren von typ-2 vaskulären endothelialen wachstumsfaktor-rezeptoren
EP1737971B1 (de)	2004-01-20	2017-08-16	Merus N.V.	Gemische bindender proteine
WO2005078122A2 (en) *	2004-02-17	2005-08-25	Nuevolution A/S	Method for enrichment involving elimination by mismatch hybridisation
DE602005017370D1 (de)	2004-03-22	2009-12-10	Nuevolution As	Ligationscodierung unter verwendung von oligonukleotidbausteinen
US20050221339A1 (en)	2004-03-31	2005-10-06	Medical Research Council Harvard University	Compartmentalised screening by microfluidic control
US20060008844A1 (en)	2004-06-17	2006-01-12	Avidia Research Institute	c-Met kinase binding proteins
JP5053089B2 (ja) *	2004-08-03	2012-10-17	ベクトン・ディキンソン・アンド・カンパニー	化合物の直接単離および多成分サンプルの分別のための磁性材料の使用
US7968287B2 (en)	2004-10-08	2011-06-28	Medical Research Council Harvard University	In vitro evolution in microfluidic systems
EP1836302B1 (de) *	2004-12-23	2010-04-14	Amersham Biosciences Corp.	Rna-amplifikation auf ligationsbasis
US20080199499A1 (en)	2005-01-12	2008-08-21	Proteonova, Inc.	Method for Making Targeted Therapeutic Agents
US10206998B2 (en)	2005-01-12	2019-02-19	Proteonova, Inc.	Modular targeted therapeutic agents and methods of making same
CA2602035C (en)	2005-03-18	2015-06-16	Medimmune, Inc.	Framework-shuffling of antibodies
WO2007011722A2 (en)	2005-07-15	2007-01-25	President And Fellows Of Harvard College	Reaction discovery system
EP2500355A3 (de)	2005-08-19	2012-10-24	Abbott Laboratories	Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
NZ612578A (en)	2005-08-19	2014-11-28	Abbvie Inc	Dual variable domain immunoglobin and uses thereof
EP1928905B1 (de)	2005-09-30	2015-04-15	AbbVie Deutschland GmbH & Co KG	Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
EP1785434A1 (de)	2005-11-11	2007-05-16	Ludwig-Maximilians-Universität München	Zielen und Folgen von Antigenen in lebenden Zellen
EP2392589A3 (de)	2005-11-11	2012-06-20	Vertex Pharmaceuticals Incorporated	Hepatitis-C-Virusvarianten
US7705138B2 (en)	2005-11-11	2010-04-27	Vertex Pharmaceuticals Incorporated	Hepatitis C virus variants
DK2339014T3 (en)	2005-11-16	2015-07-20	Ambrx Inc	Methods and compositions comprising non-natural amino acids
HRP20140240T4 (hr)	2005-11-30	2017-02-24	Abbvie Inc.	Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en)	2005-11-30	2014-04-08	Abbvie Inc.	Anti-Aβ globulomer 5F7 antibodies
PT3305900T (pt)	2005-12-01	2021-10-27	Nuevolution As	Métodos de codificação enzimática para síntese eficaz de bibliotecas grandes
WO2008010837A2 (en) *	2005-12-15	2008-01-24	The Regents Of The University Of California	Noncompetitive immunoassays to detect small molecules
WO2007081385A2 (en)	2006-01-11	2007-07-19	Raindance Technologies, Inc.	Microfluidic devices and methods of use in the formation and control of nanoreactors
CA2634987C (en) *	2006-01-17	2017-01-03	Somalogic, Inc.	Multiplexed analyses of test samples
US7846439B2 (en)	2006-02-01	2010-12-07	Cephalon Australia Pty Ltd	Domain antibody construct
WO2007092777A2 (en) *	2006-02-02	2007-08-16	Wyeth	Cloning, characterization, and application of tnfrsf19 in neurological disorders
US7749957B2 (en)	2006-04-06	2010-07-06	E.I. Du Pont De Nemours And Company	Clay-binding peptides and methods of use
US9562837B2 (en)	2006-05-11	2017-02-07	Raindance Technologies, Inc.	Systems for handling microfludic droplets
EP2530167A1 (de)	2006-05-11	2012-12-05	Raindance Technologies, Inc.	Mikrofluidische Vorrichtungen
US8178316B2 (en)	2006-06-29	2012-05-15	President And Fellows Of Harvard College	Evaluating proteins
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
MX2009000044A (es) *	2006-06-30	2009-01-23	Ambit Bios Corp	Etiqueta de acido nucleico detectable.
CA2659745A1 (en) *	2006-08-02	2008-02-07	California Institute Of Technology	Methods and systems for detecting and/or sorting targets
EP2077912B1 (de)	2006-08-07	2019-03-27	The President and Fellows of Harvard College	Fluorkohlenstoffemulsionsstabilisierende tenside
JP2010502224A (ja)	2006-09-08	2010-01-28	アボット・ラボラトリーズ	インターロイキン１３結合タンパク質
US20090252745A1 (en) *	2006-09-15	2009-10-08	Duke University	Amino acids in the HCV core polypeptide domain 3 and correlation with steatosis
MX2009005466A (es)	2006-11-22	2009-08-17	Adnexus A Bristol Myers Sqibb	Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2114443A4 (de)	2006-12-29	2011-08-10	Abbott Lab	Doppelt spezifische il-1a/il-1b-antikörper
US7855054B2 (en) *	2007-01-16	2010-12-21	Somalogic, Inc.	Multiplexed analyses of test samples
US20110136099A1 (en)	2007-01-16	2011-06-09	Somalogic, Inc.	Multiplexed Analyses of Test Samples
EP2111228B1 (de)	2007-02-02	2011-07-20	Bristol-Myers Squibb Company	10Fn3 Domain zur Behandlung von Krankheiten begleitet von unerwünschter Angiogenese
WO2008097559A2 (en)	2007-02-06	2008-08-14	Brandeis University	Manipulation of fluids and reactions in microfluidic systems
EP2118344B1 (de)	2007-02-12	2014-07-23	Proteonova, Inc.	Erzeugung von bibliotheken aus mit mrna verknüpften löslichen zufallspeptiden
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
US8592221B2 (en)	2007-04-19	2013-11-26	Brandeis University	Manipulation of fluids, fluid components and reactions in microfluidic systems
US7951559B2 (en) *	2007-07-25	2011-05-31	E.I. Du Pont De Nemours And Company	Recombinant peptide production using a cross-linkable solubility tag
US7678883B2 (en) *	2007-07-25	2010-03-16	E.I. Du Pont De Nemours And Company	Solubility tags for the expression and purification of bioactive peptides
US7829311B2 (en)	2007-07-25	2010-11-09	E.I. Du Pont De Nemours And Company	Ketosteroid isomerase inclusion body tag engineered to be acid-resistant by replacing aspartates with glutamate
US8470966B2 (en)	2007-08-10	2013-06-25	Protelica, Inc.	Universal fibronectin type III binding-domain libraries
WO2009023184A2 (en) *	2007-08-10	2009-02-19	Protelix, Inc.	Universal fibronectin type iii binding-domain libraries
US8680019B2 (en) *	2007-08-10	2014-03-25	Protelica, Inc.	Universal fibronectin Type III binding-domain libraries
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (de)	2007-09-14	2020-04-15	Adimab, LLC	Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
US7794963B2 (en)	2007-11-02	2010-09-14	E.I. Du Pont De Nemours And Company	Use of tetracysteine tags in fluorescence-activated cell sorting analysis of prokaryotic cells producing peptides or proteins
BRPI0820327A2 (pt)	2007-11-02	2020-10-06	Novartis Ag	moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
US8906700B2 (en)	2007-11-06	2014-12-09	Ambergen, Inc.	Methods and compositions for phototransfer
US8883146B2 (en)	2007-11-30	2014-11-11	Abbvie Inc.	Protein formulations and methods of making same
US8420081B2 (en)	2007-11-30	2013-04-16	Abbvie, Inc.	Antibody formulations and methods of making same
EP2229473A4 (de) *	2007-12-07	2011-02-02	Steven A Goldstein	Identifizierung von toxinliganden
AU2009213141A1 (en)	2008-02-14	2009-08-20	Bristol-Myers Squibb Company	Targeted therapeutics based on engineered proteins that bind EGFR
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
WO2009114815A1 (en)	2008-03-13	2009-09-17	Dyax Corp	Libraries of genetic packages comprising novel hc cdr3 designs
WO2009142678A1 (en)	2008-03-27	2009-11-26	Promega Corporatin	Protein labeling with cyanobenzothiazole conjugates
JP5780951B2 (ja)	2008-04-24	2015-09-16	ダイアックスコーポレーション	新規のｈｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計、ならびに新規のｌｃｃｄｒ１、ｃｄｒ２、およびｃｄｒ３設計を含む、遺伝子パッケージのライブラリ
WO2009131702A2 (en)	2008-04-25	2009-10-29	Dyax Corp.	Antibodies against fcrn and use thereof
SG190572A1 (en)	2008-04-29	2013-06-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
JP2011521626A (ja) *	2008-05-02	2011-07-28	エピセンターテクノロジーズコーポレーション	Ｒｎａポリホスファターゼの組成物、キットおよびそれらの使用
EP2116556B1 (de)	2008-05-09	2016-03-23	AbbVie Deutschland GmbH & Co KG	Antikörper zu Rezeptor für Endprodukte der fortgeschrittenen Glykierung (RAGE) und Verwendungen davon
WO2009142773A2 (en)	2008-05-22	2009-11-26	Bristol-Myers Squibb Company	Multivalent fibronectin based scaffold domain proteins
TW201006485A (en)	2008-06-03	2010-02-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en)	2008-06-03	2009-12-10	Tariq Ghayur	Dual variable domain immunoglobulins and uses thereof
AU2009270405B2 (en) *	2008-06-30	2014-06-05	Esbatech, An Alcon Biomedical Research Unit Llc	Functionalized polypeptides
TW201014602A (en)	2008-07-08	2010-04-16	Abbott Lab	Prostaglandin E2 binding proteins and uses thereof
CN102149825B (zh)	2008-07-08	2015-07-22	Abbvie公司	前列腺素e2双重可变结构域免疫球蛋白及其用途
US12038438B2 (en)	2008-07-18	2024-07-16	Bio-Rad Laboratories, Inc.	Enzyme quantification
EP4047367A1 (de)	2008-07-18	2022-08-24	Bio-Rad Laboratories, Inc.	Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken
EP2316030B1 (de)	2008-07-25	2019-08-21	Wagner, Richard W.	Proteinscreeningverfahren
NZ591543A (en) *	2008-09-30	2012-11-30	Abbott Lab	Improved antibody libraries
CA2740440A1 (en)	2008-10-14	2010-04-22	Dyax Corp.	Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis-associated pulmonary fibrosis
TWI496582B (zh)	2008-11-24	2015-08-21	必治妥美雅史谷比公司	雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20100158837A1 (en)	2008-12-18	2010-06-24	E. I. Du Pont De Nemours And Company	Iron oxide-binding peptides
US8287845B2 (en) *	2008-12-18	2012-10-16	E I Du Pont De Nemours And Company	Hair-binding peptides
US8697654B2 (en)	2008-12-18	2014-04-15	E I Du Pont De Nemours And Company	Peptide linkers for effective multivalent peptide binding
US20100158846A1 (en) *	2008-12-18	2010-06-24	E. I. Du Pont De Nemours And Company	Hair-binding peptides
US20100158822A1 (en) *	2008-12-18	2010-06-24	E .I. Du Pont De Nemours And Company	Peptides that bind to silica-coated particles
CN101768213B (zh)	2008-12-30	2012-05-30	中国科学院遗传与发育生物学研究所	一种与植物分蘖数目相关的蛋白及其编码基因与应用
ES2638324T3 (es)	2009-02-13	2017-10-19	X-Chem, Inc.	Métodos de creación y examen de bibliotecas codificadas por ADN
CN101817879A (zh)	2009-02-26	2010-09-01	中国科学院遗传与发育生物学研究所	金属硫蛋白及其编码基因与应用
TWI541021B (zh)	2009-03-05	2016-07-11	艾伯維有限公司	Ｉｌ－１７結合蛋白
WO2010111231A1 (en)	2009-03-23	2010-09-30	Raindance Technologies, Inc.	Manipulation of microfluidic droplets
US8481678B2 (en)	2009-03-30	2013-07-09	E I Du Pont De Nemours And Company	Peptide-based tooth whitening reagents
JP2012522057A (ja) *	2009-03-30	2012-09-20	ジヨンソン・アンド・ジヨンソン・コンシユーマー・カンパニーズ・インコーポレーテツド	化粧用剤の送達のためのペプチドに基づく系
US8067201B2 (en)	2009-04-17	2011-11-29	Bristol-Myers Squibb Company	Methods for protein refolding
JP2012524907A (ja)	2009-04-24	2012-10-18	ディスカヴァーエックスコーポレイション	検出可能なタンパク質を用いた細胞分析
US9085798B2 (en)	2009-04-30	2015-07-21	Prognosys Biosciences, Inc.	Nucleic acid constructs and methods of use
BR112012004546A8 (pt)	2009-08-29	2017-12-05	Abbott Lab	Terapêutica por proteínas ligantes dll4-ligantes
WO2011028811A2 (en)	2009-09-01	2011-03-10	Abbott Laboratories	Dual variable domain immunoglobulins and uses thereof
AU2010291902A1 (en)	2009-09-14	2012-04-05	Dyax Corp.	Libraries of genetic packages comprising novel HC CDR3 designs
CA2775765A1 (en) *	2009-10-05	2011-04-14	Opsonic Therapeutics Inc.	High affinity adaptor molecules for redirecting antibody specifity
US10520500B2 (en)	2009-10-09	2019-12-31	Abdeslam El Harrak	Labelled silica-based nanomaterial with enhanced properties and uses thereof
BR112012008833A2 (pt)	2009-10-15	2015-09-08	Abbott Lab	imunoglobulinas de dominio variavel duplo e usos das mesmas
WO2011049157A1 (ja)	2009-10-22	2011-04-28	ペプチドリーム株式会社	ペプチド翻訳合成におけるrapidディスプレイ法
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2691717T3 (es)	2009-10-30	2018-11-28	Novartis Ag	Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
WO2011053707A1 (en)	2009-10-31	2011-05-05	Abbott Laboratories	Antibodies to receptor for advanced glycation end products (rage) and uses thereof
US20120282276A1 (en)	2009-11-05	2012-11-08	The Regents Of The University Of Michigan	Biomarkers predictive of progression of fibrosis
WO2011058087A1 (en)	2009-11-11	2011-05-19	Gentian As	Immunoassay for assessing related analytes of different origin
EP2679234A3 (de)	2009-12-02	2014-04-23	Amgen Inc.	Bindeproteine zur Bindung an humanem FGFR1C, humanem beta-Klotho sowie humanem FGFR1C als auch humanem beta-Klotho
WO2011071943A1 (en) *	2009-12-07	2011-06-16	Prognosys Biosciences, Inc.	Peptide display arrays
MX2012006560A (es)	2009-12-08	2012-10-05	Abbott Gmbh & Co Kg	Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
US10837883B2 (en)	2009-12-23	2020-11-17	Bio-Rad Laboratories, Inc.	Microfluidic systems and methods for reducing the exchange of molecules between droplets
SMT201800552T1 (it)	2010-01-06	2018-11-09	Dyax Corp	Proteine che legano la callicreina plasmatica
US20120296403A1 (en)	2010-02-10	2012-11-22	Novartis Ag	Methods and compounds for muscle growth
US9399797B2 (en)	2010-02-12	2016-07-26	Raindance Technologies, Inc.	Digital analyte analysis
US10351905B2 (en)	2010-02-12	2019-07-16	Bio-Rad Laboratories, Inc.	Digital analyte analysis
EP4484577A3 (de)	2010-02-12	2025-03-26	Bio-Rad Laboratories, Inc.	Digitale analytanalyse
US9366632B2 (en)	2010-02-12	2016-06-14	Raindance Technologies, Inc.	Digital analyte analysis
JP2013520426A (ja)	2010-02-18	2013-06-06	ブリストル−マイヤーズスクイブカンパニー	Ｉｌ−２３に結合する、フィブロネクチンをベースとする足場ドメインタンパク質
KR101853278B1 (ko)	2010-03-02	2018-05-02	애브비 인코포레이티드	치료학적 ｄｌｌ４ 결합 단백질
US10787701B2 (en)	2010-04-05	2020-09-29	Prognosys Biosciences, Inc.	Spatially encoded biological assays
WO2011127099A1 (en)	2010-04-05	2011-10-13	Prognosys Biosciences, Inc.	Spatially encoded biological assays
US20190300945A1 (en)	2010-04-05	2019-10-03	Prognosys Biosciences, Inc.	Spatially Encoded Biological Assays
EP2558491B1 (de)	2010-04-13	2018-07-04	Bristol-Myers Squibb Company	Gerüste hergestellt aus fibronectin-proteindomänen, die an pcsk9 binden
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
EP3540059A1 (de)	2010-04-16	2019-09-18	Nuevolution A/S	Bifunktionelle komplexe und verfahren zur herstellung sowie verwendung derartiger komplexe
TW201138808A (en)	2010-05-03	2011-11-16	Bristol Myers Squibb Co	Serum albumin binding molecules
AR081246A1 (es)	2010-05-14	2012-07-18	Abbott Lab	Proteinas de union a il-1
JP6023703B2 (ja)	2010-05-26	2016-11-09	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
WO2012006500A2 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
KR102318383B1 (ko)	2010-07-16	2021-10-27	아디맵 엘엘씨	항체 라이브러리
CN107903321A (zh)	2010-07-30	2018-04-13	诺华有限公司	纤连蛋白摇篮分子和其库
EP3252072A3 (de)	2010-08-03	2018-03-14	AbbVie Inc.	Immunglobuline mit zweifacher variabler domäne und verwendungen davon
WO2012019168A2 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP3533803B1 (de)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antikörper
WO2012024650A2 (en)	2010-08-19	2012-02-23	Abbott Laboratories	Anti-ngf antibodies and their use
JP2013539364A (ja)	2010-08-26	2013-10-24	アッヴィ・インコーポレイテッド	二重可変ドメイン免疫グロブリンおよびその使用
US9562897B2 (en)	2010-09-30	2017-02-07	Raindance Technologies, Inc.	Sandwich assays in droplets
EP2625189B1 (de)	2010-10-01	2018-06-27	ModernaTX, Inc.	Manipulierte nukleinsäuren und anwendungsverfahren dafür
WO2012052391A1 (en)	2010-10-19	2012-04-26	Glaxo Group Limited	Polypeptide with jmjd3 catalytic activity
MX343607B (es)	2010-11-05	2016-11-11	Morphotek Inc	Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
EP2647720B1 (de) *	2010-12-03	2019-06-19	The University of Tokyo	Peptidbibliothek-herstellungsverfahren, peptidbibliothek und screening-verfahren
EP2647721B1 (de)	2010-12-03	2019-02-27	The University of Tokyo	Peptid mit sicherer sekundärstruktur, peptidbibliothek und herstellungsverfahren dafür
TW201307388A (zh)	2010-12-21	2013-02-16	Abbott Lab	Ｉｌ－１結合蛋白
PE20141060A1 (es)	2010-12-21	2014-09-26	Abbvie Inc	Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
CN103380143B (zh)	2010-12-22	2016-01-06	百时美施贵宝公司	结合il-23的基于纤连蛋白的支架结构域蛋白质
DE102010056289A1 (de)	2010-12-24	2012-06-28	Geneart Ag	Verfahren zur Herstellung von Leseraster-korrekten Fragment-Bibliotheken
EP3412778A1 (de)	2011-02-11	2018-12-12	Raindance Technologies, Inc.	Verfahren zur bildung gemischter tröpfchen
WO2012112804A1 (en)	2011-02-18	2012-08-23	Raindance Technoligies, Inc.	Compositions and methods for molecular labeling
US9746475B2 (en)	2011-03-14	2017-08-29	University Of Southern California	Antibody and antibody mimetic for visualization and ablation of endogenous proteins
ES2926988T3 (es)	2011-03-15	2022-10-31	X Body Inc	Métodos de cribado de anticuerpos
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
EP2694709B1 (de)	2011-04-08	2016-09-14	Prognosys Biosciences, Inc.	Peptidkonstrukte und testsysteme dafür
EP3415528B1 (de)	2011-04-13	2021-05-26	Bristol-Myers Squibb Company	Fc-fusionsproteine mit neuartigen linkern oder anordnungen
GB201106254D0 (en)	2011-04-13	2011-05-25	Frisen Jonas	Method and product
CN103732738A (zh)	2011-04-28	2014-04-16	小利兰斯坦福大学托管委员会	与样品相关的多核苷酸的鉴定
EP2709669A1 (de)	2011-05-17	2014-03-26	Bristol-Myers Squibb Company	Verfahren zur aufrechterhaltung der pegylierung von polypeptiden
EP2710382B1 (de)	2011-05-17	2017-10-18	Bristol-Myers Squibb Company	Verbesserte verfahren zur auswahl von bindungsproteinen
AU2012262007B2 (en)	2011-06-02	2017-06-22	Takeda Pharmaceutical Company Limited	Fc receptor binding proteins
US8841071B2 (en)	2011-06-02	2014-09-23	Raindance Technologies, Inc.	Sample multiplexing
EP3216872B1 (de)	2011-06-02	2020-04-01	Bio-Rad Laboratories, Inc.	Enzymquantifizierung
KR20140049993A (ko)	2011-06-02	2014-04-28	메사추세츠 인스티튜트 오브 테크놀로지	메타핵 줄기 세포의 dsRNA/DNA 하이브리드 게놈 복제 중간체
SG10201505454SA (en)	2011-07-13	2015-09-29	Abbvie Inc	Methods and compositions for treating asthma using anti-il-13 antibodies
US8658430B2 (en)	2011-07-20	2014-02-25	Raindance Technologies, Inc.	Manipulating droplet size
US9422550B2 (en)	2011-08-01	2016-08-23	The General Hospital Corporation	Protein and peptide libraries
IN2014CN02574A (de)	2011-09-07	2015-06-26	Chem Inc X
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
DE19216461T1 (de)	2011-10-03	2021-10-07	Modernatx, Inc.	Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
HK1200322A1 (en)	2011-10-24	2015-08-07	Abbvie Inc.	Immunobinders directed against sclerostin
PE20141545A1 (es)	2011-10-24	2014-11-26	Abbvie Inc	Inmunoenlazadores dirigidos contra el tnf
JP2015504038A (ja)	2011-10-31	2015-02-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	低減した免疫原性を有するフィブロネクチン結合ドメイン
AU2012347972B2 (en)	2011-12-05	2018-05-10	X-Body, Inc.	PDGF receptor beta binding polypeptides
CA2855570A1 (en)	2011-12-14	2013-06-20	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
CA3204283A1 (en)	2011-12-14	2013-06-20	AbbVie Deutschland GmbH & Co. KG	Composition and method for the diagnosis and treatment of iron-related disorders
CA3018046A1 (en)	2011-12-16	2013-06-20	Moderna Therapeutics, Inc.	Modified nucleoside, nucleotide, and nucleic acid compositions
TW202446781A (zh)	2011-12-28	2024-12-01	日商中外製藥股份有限公司	胜肽化合物之製造方法
TW201333035A (zh)	2011-12-30	2013-08-16	Abbvie Inc	針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
EP3369746A1 (de)	2012-01-27	2018-09-05	AbbVie Deutschland GmbH & Co KG	Zusammensetzung und verfahren zur diagnose und behandlung von krankheiten im zusammenhang mit neuritenabbau
GB2500243A (en) *	2012-03-15	2013-09-18	Isogenica Ltd	Identifying members of immobilised peptide libraries comprising protein-DNA complexes
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9248181B2 (en)	2012-04-20	2016-02-02	Merus B.V.	Methods and means for the production of Ig-like molecules
WO2013172954A1 (en)	2012-05-17	2013-11-21	Ra Pharmaceuticals, Inc	Peptide and peptidomimetic inhibitors
CA2875783C (en)	2012-06-06	2018-12-11	Zoetis Llc	Caninized anti-ngf antibodies and methods thereof
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
SG10201907347YA (en)	2012-07-13	2019-09-27	X Chem Inc	Dna-encoded libraries having encoding oligonucleotide linkages not readable by polymerases
ES2984405T3 (es)	2012-09-13	2024-10-29	Bristol Myers Squibb Co	Proteínas de dominio de andamio basadas en fibronectina que se unen a la miostatina
EP4592400A3 (de)	2012-10-17	2025-10-29	10x Genomics Sweden AB	Verfahren und produkt zur optimierung einer lokalisierten oder räumlichen detektion einer genexpression in einer gewebeprobe
TW202037609A (zh)	2012-11-01	2020-10-16	美商艾伯維有限公司	抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
PL2922554T3 (pl)	2012-11-26	2022-06-20	Modernatx, Inc.	Na zmodyfikowany na końcach
US9550986B2 (en)	2012-12-21	2017-01-24	Abbvie Inc.	High-throughput antibody humanization
US20160068835A1 (en)	2013-01-30	2016-03-10	Peptidream Inc.	Flexible display method
EP2951206A2 (de)	2013-02-01	2015-12-09	Bristol-Myers Squibb Company	Fibronectin-basierte gerüstproteine
EP2953968B1 (de)	2013-02-06	2018-07-25	Bristol-Myers Squibb Company	Fibronektin-typ-iii-domänenproteine mit erhöhter solubilität
US10065987B2 (en)	2013-02-12	2018-09-04	Bristol-Myers Squibb Company	High pH protein refolding methods
CA2902068C (en)	2013-02-28	2023-10-03	Caprion Proteomics Inc.	Tuberculosis biomarkers and uses thereof
EP2968587A2 (de)	2013-03-13	2016-01-20	Bristol-Myers Squibb Company	Serumalbumingebundene fibronectin-gerüstdomänen oder daran bindendes element
US10132816B2 (en)	2013-03-14	2018-11-20	Beth Israel Deaconess Medical Center, Inc.	Measurement of FGF21 as a biomarker of fructose metabolism
MX362075B (es)	2013-03-14	2019-01-07	Abbott Lab	Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
JP2016512241A (ja)	2013-03-14	2016-04-25	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	改良された抗体検出のためのｈｃｖｎｓ３組換え抗原およびこの突然変異体
WO2014143343A1 (en)	2013-03-14	2014-09-18	Abbott Laboratories	Hcv core lipid binding domain monoclonal antibodies
WO2014144280A2 (en)	2013-03-15	2014-09-18	Abbvie Inc.	DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
EP3736573A1 (de)	2013-03-15	2020-11-11	Prognosys Biosciences, Inc.	Verfahren zum nachweis von peptid/mhc/tcr-bindung
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2014189843A1 (en)	2013-05-20	2014-11-27	Board Of Trustees Of The University Of Arkansas	Gep5 model for multiple myeloma
US10183988B2 (en)	2013-06-07	2019-01-22	Duke University	Anti-Complement factor H antibodies
CA2916662C (en)	2013-06-25	2022-03-08	Prognosys Biosciences, Inc.	Methods and systems for determining spatial patterns of biological targets in a sample
MY191368A (en)	2013-06-28	2022-06-20	X Body Inc	Target antigen discovery, phenotypic screens and use thereof for identification of target cell specific target epitopes
EP3041934A1 (de)	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Chimäre polynukleotide
EP3779440A1 (de)	2013-09-23	2021-02-17	X-Body, Inc.	Verfahren und zusammensetzungen zur erzeugung von bindemitteln gegen zelloberflächenantigene
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (de)	2013-10-03	2016-08-10	Moderna Therapeutics, Inc.	Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
US11901041B2 (en)	2013-10-04	2024-02-13	Bio-Rad Laboratories, Inc.	Digital analysis of nucleic acid modification
US10288608B2 (en)	2013-11-08	2019-05-14	Prognosys Biosciences, Inc.	Polynucleotide conjugates and methods for analyte detection
EP3080158A4 (de)	2013-12-09	2018-03-21	Adimab, LLC	Polyklonale antikörpermischungen sowie verfahren zur herstellung und verwendung davon
US9944977B2 (en)	2013-12-12	2018-04-17	Raindance Technologies, Inc.	Distinguishing rare variations in a nucleic acid sequence from a sample
ES2918501T3 (es)	2013-12-19	2022-07-18	Novartis Ag	Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
GB201322692D0 (en)	2013-12-20	2014-02-05	Philochem Ag	Production of encoded chemical libraries
WO2015103367A1 (en)	2013-12-31	2015-07-09	Raindance Technologies, Inc.	System and method for detection of rna species
WO2015120058A2 (en)	2014-02-05	2015-08-13	Molecular Templates, Inc.	Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
ES2736127T3 (es)	2014-03-20	2019-12-26	Bristol Myers Squibb Co	Dominios de tipo III de fibronectina de unión a seroalbúmina
CA2943228C (en)	2014-03-20	2023-03-14	Bristol-Myers Squibb Company	Stabilized fibronectin based scaffold molecules
EP3973994A1 (de)	2014-06-12	2022-03-30	RA Pharmaceuticals, Inc.	Modulation der komplementaktivität
JP6655074B2 (ja)	2014-06-20	2020-02-26	ジェネンテック，インコーポレイテッド	シャガシンに基づく足場組成物、方法及び使用
US20170204152A1 (en)	2014-07-16	2017-07-20	Moderna Therapeutics, Inc.	Chimeric polynucleotides
TWI719942B (zh)	2014-07-21	2021-03-01	瑞士商諾華公司	使用ｃｄ３３嵌合抗原受體治療癌症
AU2015301460B2 (en)	2014-08-14	2021-04-08	Novartis Ag	Treatment of cancer using GFR alpha-4 chimeric antigen receptor
MX2017002205A (es)	2014-08-19	2017-08-21	Novartis Ag	Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
MA40772A (fr)	2014-10-02	2017-08-08	Vertex Pharma	Variants du virus de la grippe a
MA40773A (fr)	2014-10-02	2017-08-08	Vertex Pharma	Variants du virus influenza a
CA2969067A1 (en)	2014-11-25	2016-06-02	Bristol-Myers Squibb Company	Novel pd-l1 binding polypeptides for imaging
CN107207379B (zh)	2014-11-25	2021-08-10	百时美施贵宝公司	用于生物制品的18f-放射性标记的方法和组合物
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
US9937222B2 (en)	2015-01-28	2018-04-10	Ra Pharmaceuticals, Inc.	Modulators of complement activity
EP3061826A1 (de)	2015-02-27	2016-08-31	Novartis AG	Flavivirus-replikons
EP4166664A1 (de)	2015-03-13	2023-04-19	Chugai Seiyaku Kabushiki Kaisha	Modifizierte aminoacyl-trna-synthetase und verwendung davon
EP3901282B1 (de)	2015-04-10	2023-06-28	Spatial Transcriptomics AB	Räumlich getrennte multiplex-nukleinsäureanalyse von biologischen proben
JP6962819B2 (ja)	2015-04-10	2021-11-05	アディマブ，エルエルシー	親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
CN104774801A (zh) *	2015-04-14	2015-07-15	云南农业大学	一种核酸核糖体结合体系构建方法及应用
WO2016172485A2 (en)	2015-04-24	2016-10-27	Genentech, Inc.	Multispecific antigen-binding proteins
EA035332B1 (ru)	2015-04-24	2020-05-28	ВАЙВ ХЕЛТКЕР ЮКей (№5) ЛИМИТЕД	Полипептиды, нацеленные на слияние вич
CN107810198B (zh)	2015-05-29	2021-09-03	艾伯维公司	抗cd40抗体及其用途
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US20190008887A1 (en) *	2015-07-30	2019-01-10	ModernaTX Inc.	Multimeric mrna
US10647981B1 (en)	2015-09-08	2020-05-12	Bio-Rad Laboratories, Inc.	Nucleic acid library generation methods and compositions
CN108290941A (zh)	2015-09-23	2018-07-17	百时美施贵宝公司	快解离速率的血清白蛋白结合性纤连蛋白iii型结构域
CN108884147B (zh)	2015-09-23	2024-02-27	百时美施贵宝公司	结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
RU2733720C2 (ru)	2015-12-16	2020-10-06	Ра Фармасьютикалз, Инк.	Модуляторы активности комплемента
JP7069032B2 (ja)	2016-03-24	2022-05-17	ミレニアムファーマシューティカルズ，インコーポレイテッド	がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2017165742A1 (en)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3452591B1 (de)	2016-05-02	2023-08-16	Encodia, Inc.	Makromolekülanalyse mit verwendung von nukleinsäurecodierung
US10994033B2 (en)	2016-06-01	2021-05-04	Bristol-Myers Squibb Company	Imaging methods using 18F-radiolabeled biologics
JP7016323B2 (ja)	2016-06-01	2022-02-21	ブリストル－マイヤーズスクイブカンパニー	Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
US20200182884A1 (en)	2016-06-27	2020-06-11	Juno Therapeutics, Inc.	Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
EP3475706B1 (de)	2016-06-27	2021-08-11	Juno Therapeutics, Inc.	Mhc-e-beschränkte epitopen, bindungsmoleküle, und zugehörige verfahren und verwendungen
SG11201900344YA (en)	2016-07-15	2019-02-27	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CN110383068A (zh)	2016-10-03	2019-10-25	雅培实验室	评估患者样品中uch-l1状态的改进方法
BR112019006781A2 (pt)	2016-10-07	2019-07-30	Novartis Ag	receptores de antígeno quiméricos para o tratamento de câncer
KR20190093196A (ko)	2016-12-07	2019-08-08	라 파마슈티컬스 인코포레이티드	보체 활성의 조절인자
CN110290811A (zh)	2017-01-13	2019-09-27	中央研究院	用以治疗脑部疾病的可重复装载的水胶系统
US11135164B2 (en)	2017-01-13	2021-10-05	Academia Sinica	Reloadable hydrogel system comprising an anti-PEG antibody for treating myocardial infarction
JP7187323B2 (ja)	2017-01-31	2022-12-12	中外製薬株式会社	無細胞翻訳系におけるペプチドの合成方法
AU2018236568B2 (en) *	2017-03-17	2021-07-01	Cubicstars, Inc.	Method for producing complex of RNA molecule and peptide, and utilization thereof
CA3261113A1 (en)	2017-03-23	2025-10-27	Abbott Laboratories	Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018191531A1 (en)	2017-04-15	2018-10-18	Abbott Laboratories	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
ES3053676T3 (en)	2017-04-28	2026-01-23	Abbott Lab	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
US10866251B2 (en)	2017-05-25	2020-12-15	Abbott Laboratories	Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP7269182B2 (ja)	2017-05-30	2023-05-08	アボット・ラボラトリーズ	心臓トロポニンｉ及び早期バイオマーカーを使用する、ヒト対象における軽度外傷性脳損傷を診断及び査定する一助となるための方法
EP3933408A1 (de)	2017-05-30	2022-01-05	Nant Holdings IP LLC	Zirkulierende tumorzellenanreicherung unter verwendung von neoepitopen
KR20250007021A (ko)	2017-06-09	2025-01-13	추가이 세이야쿠 가부시키가이샤	N-치환 아미노산을 포함하는 펩타이드의 합성 방법
US11169159B2 (en)	2017-07-03	2021-11-09	Abbott Laboratories	Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
EP3688165A4 (de)	2017-09-25	2021-09-29	Nant Holdings IP, LLC	Validierung der präsentation von neoepitopen
EP3692370A2 (de)	2017-10-04	2020-08-12	OPKO Pharmaceuticals, LLC	Artikel und verfahren zur personalisierten krebstherapie
CA3080120C (en)	2017-10-27	2023-11-21	New York University	Anti-galectin-9 antibodies and uses thereof
JP7390027B2 (ja)	2017-10-31	2023-12-01	エンコディア，インコーポレイテッド	核酸エンコーディングおよび／または標識を使用する解析のためのキット
JP7379165B2 (ja)	2017-12-09	2023-11-14	アボット・ラボラトリーズ	Ｇｆａｐとｕｃｈ－ｌ１との組合せを使用する、ヒト対象における外傷性脳損傷を診断及び査定する一助となるための方法
EP3721233A2 (de)	2017-12-09	2020-10-14	Abbott Laboratories	Verfahren zur unterstützung bei der diagnose und bewertung eines patienten, der eine orthopädische verletzung erlitten hat und der eine verletzung des kopfes wie eine leichte traumatische hirnverletzung (tbi) hat oder möglicherweise erlitten hat, unter verwendung eines glialen fibrillären sauren proteins (gfap) und/oder einer ubiquitin-carboxy-terminalen hydrolase l1 (uch-l1)
WO2019117274A1 (ja)	2017-12-15	2019-06-20	中外製薬株式会社	ペプチドの製造方法、及び塩基の処理方法
US20240239877A1 (en)	2017-12-18	2024-07-18	Viiv Healthcare Uk (No. 5) Limited	Antigen binding polypeptides
BR112020017701A2 (pt)	2018-03-12	2020-12-29	Zoetis Services Llc	Anticorpos anti-ngf e métodos dos mesmos
EP3775261B1 (de)	2018-03-26	2025-09-17	Guangzhou Chengyuan Bioimmunology Technology Co., Ltd.	Zusammensetzungen zielbindender einheiten und verwendungsverfahren
EP3878836B1 (de)	2018-11-07	2025-07-23	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur herstellung von o-substituierten serinderivaten
WO2020111238A1 (ja)	2018-11-30	2020-06-04	中外製薬株式会社	ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法
US12084500B2 (en)	2019-01-23	2024-09-10	New York University	Antibodies specific to delta 1 chain of T cell receptor
KR102592844B1 (ko) *	2019-02-15	2023-10-20	아트레카, 인크.	종양 조직에 결합하는 항체, 및 그의 진단 및 치료 용도
EP3939962A4 (de)	2019-03-15	2022-12-28	Chugai Seiyaku Kabushiki Kaisha	Verfahren zur herstellung eines aromatischen aminosäurederivates
US20220169706A1 (en)	2019-03-28	2022-06-02	Danisco Us Inc	Engineered antibodies
BR112021021673A2 (pt)	2019-05-09	2021-12-21	Genentech Inc	Método para melhorar o emparelhamento preferencial de uma cadeia pesada e uma cadeia leve de um anticorpo e anticorpo
JP2022535411A (ja)	2019-06-04	2022-08-08	ラファーマシューティカルズインコーポレイテッド	補体阻害剤による炎症性疾患治療
KR20220044534A (ko)	2019-08-13	2022-04-08	엘피스 바이오파마슈티컬즈	조작된 인터류킨-2 수용체 베타 효능제
BR112022007535A2 (pt)	2019-11-07	2022-07-12	Chugai Pharmaceutical Co Ltd	Composto peptídico cíclico tendo ação inibitória de kras
WO2021091611A1 (en)	2019-11-08	2021-05-14	10X Genomics, Inc.	Spatially-tagged analyte capture agents for analyte multiplexing
KR20220137698A (ko)	2020-02-05	2022-10-12	라리마 테라퓨틱스, 인코포레이티드	Tat 펩티드 결합 단백질 및 이의 용도
WO2021174045A1 (en)	2020-02-28	2021-09-02	Bristol-Myers Squibb Company	Radiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
EP4136459A1 (de)	2020-04-13	2023-02-22	Abbott Laboratories	Verfahren, komplexe und kits zum nachweis oder zur bestimmung einer menge eines ss-coronavirus-antikörpers in einer probe
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
US12252525B2 (en)	2020-07-31	2025-03-18	Nantbio, Inc.	Chimeric T cell receptors, nucleic acids, and methods of making and using the same
CA3188349A1 (en)	2020-08-04	2022-02-10	A. Scott Muerhoff	Improved methods and kits for detecting sars-cov-2 protein in a sample
US12553898B1 (en)	2020-08-10	2026-02-17	10X Genomics, Inc.	Fluorescent hybridization of antibody-oligonucleotide for multiplexing and signal amplification
WO2022104001A1 (en)	2020-11-13	2022-05-19	Bristol-Myers Squibb Company	Expanded protein libraries and uses thereof
US20220170948A1 (en)	2020-12-01	2022-06-02	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en)	2021-11-30	2023-06-08	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
EP4729631A2 (de)	2020-12-21	2026-04-22	10X Genomics, Inc.	Verfahren, zusammensetzungen und systeme zur erfassung von sonden und/oder barcodes
EP4271998A1 (de)	2020-12-30	2023-11-08	Abbott Laboratories	Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
JP2024504372A (ja)	2021-01-22	2024-01-31	エルピス・バイオファーマシューティカルズ	抗ｐｄ－ｌ１モノクローナル抗体及びインターロイキン１５（ｉｌ－１５）、インターロイキン１５受容体１５アルファまたはインターロイキン２との融合タンパク質
US12561946B2 (en)	2021-03-12	2026-02-24	Eagle Technology, Llc	Object detection device incorporating quantum computing and game theoretic optimization and related methods
US11792839B2 (en)	2021-03-12	2023-10-17	Eagle Technology, Llc	Systems and methods for controlling communications based on machine learned information
US12265882B2 (en)	2021-03-12	2025-04-01	Eagle Technology, Llc	Systems and methods for quantum computing based subset summing
AU2022238446A1 (en)	2021-03-18	2023-09-07	10X Genomics, Inc.	Multiplex capture of gene and protein expression from a biological sample
BR112023022439A2 (pt)	2021-04-26	2023-12-26	Celanese Eva Performance Polymers Llc	Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US20220381796A1 (en)	2021-05-18	2022-12-01	Abbott Laboratories	Methods of evaluating brain injury in a pediatric subject
WO2022256503A1 (en)	2021-06-03	2022-12-08	10X Genomics, Inc.	Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
WO2022266034A1 (en)	2021-06-14	2022-12-22	Abbott Laboratories	Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
JP2024534849A (ja)	2021-08-31	2024-09-26	アボット・ラボラトリーズ	脳の損傷を診断する方法及びシステム
CN118715440A (zh)	2021-08-31	2024-09-27	雅培实验室	诊断脑损伤的方法和系统
JP2024538608A (ja)	2021-09-30	2024-10-23	アボット・ラボラトリーズ	脳の損傷を診断する方法及びシステム
WO2023102118A2 (en)	2021-12-01	2023-06-08	10X Genomics, Inc.	Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis
EP4448179A1 (de)	2021-12-17	2024-10-23	Abbott Laboratories	Systeme und verfahren zur bestimmung von uch-l1, gfap und anderen biomarkern in blutproben
WO2023150652A1 (en)	2022-02-04	2023-08-10	Abbott Laboratories	Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
CN119731199A (zh)	2022-05-10	2025-03-28	艾佩斯瑞生物制药公司	工程化的白细胞介素-2受体β降低结合的激动剂
CN120167040A (zh)	2022-06-29	2025-06-17	雅培实验室	用于确定生物样本中的gfap的磁性定点照护型系统和测定
JP2025532597A (ja)	2022-09-15	2025-10-01	アボット・ラボラトリーズ	軽度及び超軽度の外傷性脳損傷を区別するためのバイオマーカー及び方法
EP4640846A1 (de)	2022-12-23	2025-10-29	Peptidream Inc	Dna-amplifikationsverfahren mittels pcr
WO2024211475A1 (en)	2023-04-04	2024-10-10	Abbott Laboratories	Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024225483A1 (ja)	2023-04-28	2024-10-31	ペプチドリーム株式会社	リンカー
EP4713682A1 (de)	2023-04-28	2026-03-25	Abbott Point of Care Inc.	Verbesserte tests, kartuschen und kits zum nachweis von biomarkern, einschliesslich biomarkern für hirnverletzungen
TW202448509A (zh)	2023-05-12	2024-12-16	美商建南德克公司	減少抗體黏度之方法及組成物
WO2026060324A1 (en)	2024-09-13	2026-03-19	Ormoni Biosciences, Inc.	Peptide libraries having improved functional pharmacokinetic parameters and methods of synthesis and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4587044A (en)	1983-09-01	1986-05-06	The Johns Hopkins University	Linkage of proteins to nucleic acids
DE229046T1 (de)	1985-03-30	1987-12-17	Marc Genf/Geneve Ballivet	Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5273882A (en) *	1985-06-13	1993-12-28	Amgen	Method and kit for performing nucleic acid hybridization assays
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5391723A (en) *	1989-05-31	1995-02-21	Neorx Corporation	Oligonucleotide conjugates
US5800992A (en) *	1989-06-07	1998-09-01	Fodor; Stephen P.A.	Method of detecting nucleic acids
US5143854A (en)	1989-06-07	1992-09-01	Affymax Technologies N.V.	Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
AU638762B2 (en)	1989-10-05	1993-07-08	Optein Inc	Cell-free synthesis and isolation of novel genes and polypeptides
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
AU8498091A (en) *	1990-08-02	1992-03-02	Regents Of The University Of Colorado, The	Systematic polypeptide evolution by reverse translation
US5843701A (en) *	1990-08-02	1998-12-01	Nexstar Pharmaceticals, Inc.	Systematic polypeptide evolution by reverse translation
US5264563A (en)	1990-08-24	1993-11-23	Ixsys Inc.	Process for synthesizing oligonucleotides with random codons
DE69132531T2 (de)	1990-12-06	2001-09-13	Affymetrix, Inc. (N.D.Ges.D.Staates Delaware)	Verbindungen und ihre Verwendung in einer binären Synthesestrategie
ATE126599T1 (de) *	1991-01-22	1995-09-15	Akzo Nobel Nv	Verfahren zur bestimmung von anti-rns- antikörpern.
US5795747A (en)	1991-04-16	1998-08-18	Evotec Biosystems Gmbh	Process for manufacturing new biopolymers
DE4112440C1 (de)	1991-04-16	1992-10-22	Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De
WO1993003172A1 (en) *	1991-08-01	1993-02-18	University Research Corporation	Systematic polypeptide evolution by reverse translation
US5639603A (en)	1991-09-18	1997-06-17	Affymax Technologies N.V.	Synthesizing and screening molecular diversity
US5733731A (en)	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
US5652094A (en) *	1992-01-31	1997-07-29	University Of Montreal	Nucleozymes
US5541061A (en)	1992-04-29	1996-07-30	Affymax Technologies N.V.	Methods for screening factorial chemical libraries
US5635602A (en)	1993-08-13	1997-06-03	The Regents Of The University Of California	Design and synthesis of bispecific DNA-antibody conjugates
WO1995011922A1 (en) *	1993-10-29	1995-05-04	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
US5561043A (en)	1994-01-31	1996-10-01	Trustees Of Boston University	Self-assembling multimeric nucleic acid constructs
DE69534347T2 (de)	1994-01-31	2006-05-24	Trustees Of Boston University, Boston	Bibliotheken aus Polyklonalen Antikörpern
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5627024A (en)	1994-08-05	1997-05-06	The Scripps Research Institute	Lambdoid bacteriophage vectors for expression and display of foreign proteins
US5559000A (en) *	1995-01-18	1996-09-24	The Scripps Research Institute	Encoded reaction cassette
DE19646372C1 (de) *	1995-11-11	1997-06-19	Evotec Biosystems Gmbh	Genotyp und Phänotyp koppelnde Verbindung
DE69730157T2 (de) *	1996-10-17	2005-07-28	Mitsubishi Chemical Corp.	Molekül, welches genotyp und phänotyp zusammenführt und dessen anwendungen
GB9703369D0 (en)	1997-02-18	1997-04-09	Lindqvist Bjorn H	Process
GB9712512D0 (en)	1997-06-16	1997-08-20	Bioinvent Int Ab	A method for in vitro molecular evolution of protein function
US5985575A (en)	1998-05-20	1999-11-16	Wisconsin Alumni Research Foundation	Tethered function assay for protein function

1998
- 1998-01-14 AT AT98904574T patent/ATE332368T1/de active
- 1998-01-14 ES ES98904574T patent/ES2268763T3/es not_active Expired - Lifetime
- 1998-01-14 EP EP06013825A patent/EP1712623B1/de not_active Expired - Lifetime
- 1998-01-14 RU RU99118585/13A patent/RU2233878C2/ru active
- 1998-01-14 DK DK06013825.2T patent/DK1712623T3/da active
- 1998-01-14 US US09/007,005 patent/US6258558B1/en not_active Expired - Lifetime
- 1998-01-14 IL IL13101698A patent/IL131016A/en not_active IP Right Cessation
- 1998-01-14 CA CA2278786A patent/CA2278786C/en not_active Expired - Lifetime
- 1998-01-14 AT AT06013825T patent/ATE529509T1/de active
- 1998-01-14 ES ES06013825T patent/ES2373110T3/es not_active Expired - Lifetime
- 1998-01-14 EP EP98904574A patent/EP0971946B1/de not_active Expired - Lifetime
- 1998-01-14 CN CNB988035111A patent/CN1238366C/zh not_active Expired - Lifetime
- 1998-01-14 JP JP53453498A patent/JP3692542B2/ja not_active Expired - Lifetime
- 1998-01-14 KR KR1019997006594A patent/KR100566859B1/ko not_active Expired - Lifetime
- 1998-01-14 PT PT06013825T patent/PT1712623E/pt unknown
- 1998-01-14 PT PT98904574T patent/PT971946E/pt unknown
- 1998-01-14 WO PCT/US1998/000807 patent/WO1998031700A1/en not_active Ceased
- 1998-01-14 AU AU62419/98A patent/AU738328B2/en not_active Expired
- 1998-01-14 DK DK98904574T patent/DK0971946T3/da active
- 1998-01-14 DE DE69835143T patent/DE69835143T2/de not_active Expired - Lifetime
- 1998-01-15 TW TW087100513A patent/TW589323B/zh not_active IP Right Cessation
1999
- 1999-01-28 US US09/238,710 patent/US6518018B1/en not_active Expired - Lifetime
- 1999-02-05 US US09/244,794 patent/US6214553B1/en not_active Expired - Lifetime
- 1999-02-05 US US09/244,796 patent/US6281344B1/en not_active Expired - Lifetime
- 1999-10-29 US US09/430,049 patent/US6207446B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
PT1712623E (pt)	2011-12-21
JP3692542B2 (ja)	2005-09-07
ES2268763T3 (es)	2007-03-16
PT971946E (pt)	2006-11-30
US6518018B1 (en)	2003-02-11
CN1238366C (zh)	2006-01-25
EP1712623A2 (de)	2006-10-18
ES2373110T3 (es)	2012-01-31
DK1712623T3 (da)	2012-02-06
TW589323B (en)	2004-06-01
US6281344B1 (en)	2001-08-28
US6214553B1 (en)	2001-04-10
US6207446B1 (en)	2001-03-27
EP0971946B1 (de)	2006-07-05
US6258558B1 (en)	2001-07-10
ATE529509T1 (de)	2011-11-15
IL131016A0 (en)	2001-01-28
EP1712623A3 (de)	2008-10-15
KR100566859B1 (ko)	2006-04-03
CA2278786A1 (en)	1998-07-23
CN1251593A (zh)	2000-04-26
EP1712623B1 (de)	2011-10-19
EP0971946A4 (de)	2002-12-04
DK0971946T3 (da)	2006-10-30
AU738328B2 (en)	2001-09-13
HK1027577A1 (en)	2001-01-19
DE69835143T2 (de)	2007-06-06
EP0971946A1 (de)	2000-01-19
CA2278786C (en)	2010-07-20
JP2002513281A (ja)	2002-05-08
ATE332368T1 (de)	2006-07-15
RU2233878C2 (ru)	2004-08-10
AU6241998A (en)	1998-08-07
DE69835143D1 (de)	2006-08-17
KR20000070361A (ko)	2000-11-25
WO1998031700A1 (en)	1998-07-23

Legal Events

Date	Code	Title
2005-05-17	FF	Patent granted
2005-09-25	KB	Patent renewed
2008-02-10	KB	Patent renewed
2012-01-31	KB	Patent renewed
2015-12-31	KB	Patent renewed
2018-08-30	EXP	Patent expired

Publication	Publication Date	Title
US6518018B1 (en)	2003-02-11	RNA-antibody fusions and their selection
CA2361725C (en)	2011-04-12	Selection of proteins using rna-protein fusions
US8207093B2 (en)	2012-06-26	Selection of proteins using RNA-protein fusions
AU776478B2 (en)	2004-09-09	Selection of proteins using RNA-protein fusions